Tom Davidson

Tom Davidson is Vice Chairman, Co- President, and Global Co-Head of Investment Banking.  He serves on the Firm’s executive committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Tom is focused on building a world class Mergers & Acquisitions business at Leerink Partners.

Over the last decade, Tom has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.

Tom joined the Firm in 2024 from PJT Partners where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.

Tom graduated from Yale University, summa cum laude and Phi Beta Kappa, with a BA in Economics and received his MBA from the Wharton School of the University of Pennsylvania.  Tom is a member of the Board of Trustees of the Rye Country Day School in Rye, NY.